Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program

Launched by GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO · Feb 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called daratumumab, which is being tested in adults with a type of blood cancer known as very high risk T-lymphoblastic leukemia (T-ALL). The main goal is to find out if adding daratumumab to the usual treatment helps more patients become free of minimal residual disease (MRD) after the initial phase of therapy. MRD means that there are no remaining cancer cells that can be detected, which is an important sign of effective treatment.

To be eligible for this trial, participants should be between 18 and 65 years old and must have a confirmed diagnosis of T-ALL. They need to provide samples of their bone marrow or blood for testing and have a significant percentage of cancer cells in their diagnosis. Participants will receive daratumumab along with a treatment plan inspired by successful pediatric protocols. Throughout the trial, patients will be monitored closely, and they’ll need to agree to use effective contraception if they are capable of having children. This trial is currently recruiting participants, and it's a chance for those with this challenging condition to access potentially beneficial treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18-65 years.
• • 2. A diagnosis of T-ALL according to the 2022 International Consensus Classification (ICC) is required, either de novo or secondary to chemo-radiotherapy for another cancer. Pre-treatment with low-dose corticosteroids +/- cyclophosphamide in patients presenting with hyperleukocytosis is allowed.
• • 3. Availability of fresh bone marrow (BM) (or peripheral blood (PB) in patients with hyperleukocytosis) samples to perform diagnostic procedures. ).
• • 4. Bone marrow blast percentage at diagnosis ≥20%.
• • 5. CD38 positivity on ALL blasts (any level of positivity).
• • 6. ETP and near ETP at diagnosis according to internationally accepted criteria (appendix G) at diagnosis or other VHR T-ALL subtypes (WBC count \>100 x109/L; complex karyotype with ≥5 unrelated anomalies; other CD1a-negative immunophenotypes). T-Myeloid MPAL according to the 2022 ICC of Acute Leukemias of Ambiguous Lineage (appendix H) can also be eligible and considered as VHR.
• • 7. Availability of full cytological, cytochemical, immunophenotypic, cytogenetic and molecular disease characterization according to the EGIL and WHO classifications.
• • 8. An ECOG performance status 0-2, unless a performance of 3 is unequivocally caused by the disease itself, (and not by pre-existing comorbidities,) and is considered and/or documented to be reversible following the application of anti-leukemic therapy and appropriate supportive measures.
• • 9. For females of childbearing potential, a negative pregnancy test must be documented. Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from enrollment through 12 months after the end of treatment.
• • 10. Signed written informed consent according to ICH/E U/GCP and national local laws.
• Exclusion Criteria:
• • 1. Diagnosis of B-lineage ALL, and Ph+ ALL.
• • 2. Down's syndrome.
• • 3. Prior systemic chemotherapy for ALL (excluding cyclophosphamide during pre-phase).
• • 4. Pre-existing, uncontrolled pathology such as heart failure (congestive/ischemic, acute myocardial infarction within the past 3 months, untreatable arrhythmias, NYHA classes III and IV), severe liver disease with serum direct bilirubin \>3 mg/dL (unless attributable to Gilbert' syndrome or ALL) and/or ALT \>5x upper normal limit (unless attributable to ALL), kidney function impairment with serum creatinine \>2 mg/dL (unless attributable to ALL), and severe neuropsychiatric disorder that impairs the patient's ability to understand and sign the informed consent, or to cope with the intended treatment plan. N.B. For altered liver and kidney function tests, eligibility criteria can be reassessed at 24-96 hours, following the institution of adequate supportive measures.
• • 5. Presence of serious, active, uncontrolled infections.
• • 6. A history of cancer that is not in a remission phase following surgery and/or radiotherapy and/or chemotherapy, with a life expectancy \<2 years.
• • 7. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.